Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 2/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL551616 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783375 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783374 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL22607961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24340812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24033081 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL4165739 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24612535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL21283002 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL6227411 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263546-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | claimed |
| EP-4263548-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | claimed |
| EP-4263547-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | claimed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | claimed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | claimed |
| EP-1713480-B1 | THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS | PHARMENA SA (PL) | 2011-09-14 | — | — | EP | claimed |
| EP-2279738-A1 | The use of quaternary pyridinium salts as vasoprotective agents | Pharmena SA (PL) | 2011-02-02 | — | — | EP | claimed |
| US-20080207702-A1 | Prevent diseases of vascular system, oxidative stresses; controlling concentration of prostaglandin 12; anticholesterol agents; insulin resistance; antidiabetic agents; antiinflammatory agents ; antiarthritic agents; thrombosis; adult respiratory distress syndrome ; neurodegenerative diseases | PHARMENA SP Z O.O (PL) | 2008-08-28 | — | — | US | claimed |
| EP-1713480-A2 | THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS | Pharmena Sp Zo.o. (PL) | 2006-10-25 | — | — | EP | claimed |
| WO-2005067927-A2 | THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS | PHARMENA SP Z O.O. (PL) | 2005-07-28 | — | — | WO | claimed |
| US-20260139327-A1 | MORPHOMETRIC GENOTYPING OF CELLS USING OPTICAL TOMOGRAPHY FOR DETECTING TUMOR MUTATIONAL BURDEN | VISIONGATE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12622949-B2 | Compositions containing rapid-acting insulin analogues | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612663-B2 | Morphometric detection of DNA mismatch repair deficiency | VISIONGATE, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12516380-B2 | Morphometric genotyping of cells using optical tomography for detecting tumor mutational burden | VISIONGATE, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025229177-A1 | CRYSTALLINE FORMS OF AN N-SUBSTITUTED INDOLE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-06 | — | — | WO | disclosed |
| EP-0142027-A1 | 5-Substituted-delta-2-imidazolinyl-thio ethers, and process for their production | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-22 | — | — | EP | disclosed |
| EP-0100900-A1 | Novel (3.2.0.) bicycloheptanone oxime ethers with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1984-02-22 | — | — | EP | disclosed |
| EP-0065200-A2 | Thiolactime ethers of delta-1-pyrrolidine, and their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-11-24 | — | — | EP | disclosed |
| EP-0055851-A1 | 11-Deoxy-hetero-imino-prostacyclins, processes for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-07-14 | — | — | EP | disclosed |
| EP-0034778-A1 | Hetero-imino-prostacyclins and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207702-A1 | Prevent diseases of vascular system, oxidative stresses; controlling concentration of prostaglandin 12; anticholesterol agents; insulin resistance; antidiabetic agents; antiinflammatory agents ; antiarthritic agents; thrombosis; adult respiratory distress syndrome ; neurodegenerative diseases | TXN2, TXNRD2, PTGIS | PTGIR 7/4885ALDH1A1 4423/4885MEN1 3020/4885 |
| US-12612663-B2 | Morphometric detection of DNA mismatch repair deficiency | MSH2, MSH6, PDCD10 | PTGIR 2981/4885ALDH1A1 2228/4885MEN1 198/4885 |
| US-12622949-B2 | Compositions containing rapid-acting insulin analogues | IAPP, HBB, GLP1R | PTGIR 779/4885ALDH1A1 4789/4885MEN1 1528/4885 |
| US-20260139327-A1 | MORPHOMETRIC GENOTYPING OF CELLS USING OPTICAL TOMOGRAPHY FOR DETECTING TUMOR MUTATIONAL BURDEN | CD274, MSH2, PDCD1 | PTGIR 4302/4885ALDH1A1 2571/4885MEN1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.